Stockhouse: Optimi Health makes first international MDMA shipment

Optimi Health (CSE:OPTI) revealed it has made its first international shipment of MDMA to The Institute for Psychedelic Research at Tel Aviv University.

The company stated in a news release it obtained an export permit that is required from Health Canada to ship its in-house manufactured MDMA active pharmaceutical ingredient (APIR) to the university in Israel.

The permit also means Optimi Health is one of the first psychedelics’ pharmaceutical companies to ship MDMA to the country.

Full story here.

ABOUT OPTIMI

(CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

FORWARD‐LOOKING STATEMENTS

Products do not contain psilocybin

Search
Get news & updates directly to your inbox.
Interested In Optimi? Let's Talk.